A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal Carcinoma
This is a randomized, open-label, multicenter phase Ⅲ trial to evaluate the efficacy and safety of SYS6010 combined with Enlonstobart injection versus Tislelizumab combined with chemotherapy (gemcitabine plus cisplatin) in patients with previously systemic treatment-naive recurrent or metastatic nasopharyngeal carcinoma